Technology | 2015.06.09
ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
CLEVELAND--(BUSINESS WIRE)--ImageIQ, an innovative Imaging Software and Contract Research Organization for preclinical research and clinical trials, announced today that it has been chosen by ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies, to provide its full complement of clinical research imaging support services and technology for ContraVir’s Phase III clinical trial of FV-100, an orally available nucleosi
For more information, please visit
http://www.businesswire.com/news/home/20[...]ects-ImageIQ-Imaging-CRO-Phase
